Inhibrx Biosciences, Inc. (INBX)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$121.17-0.89%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · INBX
Income statement, balance sheet, and cash flow — annual and quarterly history, as reported.
Figures in millions of None, except per-share and ratios.
| TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | |
|---|---|---|---|---|---|
| Revenues | |||||
| Revenues | — | 1.3 | 0.2 | 1.8 | — |
| Total Revenues | — | 1.3 | 0.2 | 1.8 | — |
| Operating Expenses & Income | |||||
| R&D Expenses | 103.0 | 113.0 | 203.7 | 191.6 | — |
| Operating Income | (127.8) | (135.0) | (331.4) | (219.2) | — |
| Earnings from Continuing Operations | |||||
| Interest Expense | — | 12.2 | 13.5 | — | — |
| Other Non-Operating Income / Expenses | (10.4) | (5.0) | 2,019.0 | (20.5) | — |
| EBT, Incl. Unusual Items | (138.2) | (140.1) | 1,687.6 | (239.7) | — |
| Income Tax Expense | — | 0.0 | 0.0 | 0.0 | — |
| Net Income | |||||
| Net Income | (138.2) | (140.1) | 1,687.6 | (241.4) | — |
| Per Share | |||||
| Basic EPS | (8.82) | (9.04) | 114.01 | (20.48) | — |
| Diluted EPS | (8.82) | (9.04) | 112.62 | (20.48) | — |
| Basic Weighted Avg Shares | 15.7 | 15.5 | 14.8 | 11.8 | — |
| Diluted Weighted Avg Shares | 15.7 | 15.5 | 15.0 | 11.8 | — |
| Supplemental | |||||
| EBITDA | — | (132.5) | (329.2) | (218.0) | — |
| EBIT | (127.8) | (135.0) | (331.4) | (219.2) | — |
| Effective Tax Rate | — | — | — | -0.0% | — |
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.